Achieve Life Sciences (ACHV) Stock Forecast, Price & News

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ACHV shares.
View ACHV analyst ratings or view top-rated stocks.

2 analysts have issued 1-year price objectives for Achieve Life Sciences' stock. Their ACHV share price forecasts range from $17.00 to $20.00. On average, they predict the company's stock price to reach $18.67 in the next year. This suggests a possible upside of 332.1% from the stock's current price.
View analysts price targets for ACHV or view top-rated stocks among Wall Street analysts.

Achieve Life Sciences' stock was trading at $2.45 at the start of the year. Since then, ACHV shares have increased by 76.3% and is now trading at $4.32.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 13th 2023.
View our ACHV earnings forecast.

Achieve Life Sciences, Inc. (NASDAQ:ACHV) released its quarterly earnings data on Monday, August, 14th. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.41) by $0.02.

Achieve Life Sciences's stock reverse split before market open on Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, July 30th 2020. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some companies that other Achieve Life Sciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Gran Tierra Energy (GTE), Bionano Genomics (BNGO), Novan (NOVN), Aeterna Zentaris (AEZS), Zosano Pharma (ZSAN), CNBX Pharmaceuticals (CNBX), KushCo (KSHB) and Pennsylvania Real Estate Investment Trust (PEI).

Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."

Achieve Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Shay Capital LLC (4.30%), AWM Investment Company Inc. (1.51%), B. Riley Wealth Advisors Inc. (1.20%), Geode Capital Management LLC (0.90%), LPL Financial LLC (0.82%) and Raymond James & Associates (0.76%).
View institutional ownership trends.

Shares of ACHV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ACHV stock can currently be purchased for approximately $4.32.

Achieve Life Sciences (NASDAQ:ACHV) has a market capitalization of $91.20 million. The biopharmaceutical company earns $-42,350,000.00 in net income (profit) each year or ($3.11) on an earnings per share basis.

Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The official website for the company is achievelifesciences.com. The biopharmaceutical company can be reached via phone at (604) 210-2217, via email at jwong@bplifescience.com, or via fax at 425-686-1600.